Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

VJVirtual | NLGN1: potential biomarker of Alzheimer’s disease

Jonathan Brouillette • 6 May 2020
Alzheimer’s Disease

Jonathan Brouillette, PhD, University of Montreal, Montreal, Quebec, Canada, discusses neuroligin-1 (NLGN1) as an early biomarker of Alzheimer’s disease (AD). This interview was recorded during an online conference call with The Video Journal of Dementia (VJDementia).

More from Jonathan Brouillette

1:22
Neuroligin-1 is altered in Alzheimer’s disease
Jonathan Brouillette • 6 May 2020

Related Videos

2:33
Anti-amyloid therapy for Alzheimer's disease: beyond the 18-month mark
Dorota Religa • 22 Mar 2024
0:50
Will long-term anti-amyloid treatment show greater clinical benefit?
Dorota Religa • 22 Mar 2024
1:24
Digital frailty screening in dementia
Dorota Religa • 22 Mar 2024
4:19
Current projects from Alzheimer’s Disease International
Paola Barbarino • 23 Mar 2024
The content of VJDementia is intended for healthcare professionals